Catalyst Pharmaceutical Partners (CPRX)

[dough_maker]

The more I think about this article by AF, the more questions I have. But they are all about the intent of the article than anything else.

He has outlined no path through which Jacobus could get the Orphan Drug designation for them selves or how they can stop CPRX. Jacobus is still at the level of phase II trial. CPRX is doing a phase III study. The article's main claim is that the existence of Jacobus is a risk that investors haven't seen. But I see no path through which Jacobus can finish ahead both on the basis of timeline and the capital required to do such work. The main risk to CPRX is the one all investors are (and have been) aware of - that some clinical trials fail. That is it. I think people will come to their senses next week (or at least I hope so).

Authors, especially those who have achieved the power to influence success or failure of stocks (even on a short term basis), should know their position comes with responsibility. There are people at the end of these trades who win or lose. This is not a game. Legitimate questions should be raised of course, but half baked articles that come from an "I do it because I can" attitude are evil. There is nothing substantive in the article that explains the path through which Jacobus poses a risk to CPRX despite that being the core of the message of the article. Every time such issue is broached, AF says something like 'they are working hard to stop cprx'. The question is how? The writer knows he has no answer - that is why he is quiet. This can only be by design in my mind.